Skip to main content
Erschienen in: Journal of Neurology 11/2014

01.11.2014 | Original Communication

Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD)

verfasst von: Anna De Rosa, Claudia Carducci, Carla Carducci, Silvio Peluso, Maria Lieto, Andrea Mazzella, Francesco Saccà, Vincenzo Brescia Morra, Sabina Pappatà, Vincenzo Leuzzi, Giuseppe De Michele

Erschienen in: Journal of Neurology | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

The clinical diagnosis of Parkinson’s Disease (PD) is not supported by Single Photon Emission Computed Tomography (SPECT) using dopamine transporter radioligand in 4–15 % of patients. It has been hypothesized that this phenomenon, named “Scans Without Evidence of Dopaminergic Deficiency” (SWEDD), may be an adult-onset dystonia. We investigated the hypothesis that these patients might be affected by Dopa-Responsive Dystonia (DRD). We enrolled eleven unrelated patients (8 F and 3 M) with clinical parkinsonism and normal [123I]FP-CIT SPECT. The GTP-cyclohydrolase1 (GCH1) gene was sequenced in all patients; urine biopterin and neopterin analysis was carried out in nine and oral phenylalanine (Phe) loading in seven. Neurological examination showed bradykinesia and resting/postural tremor in all patients, and rigidity in ten, suggesting a clinical diagnosis of PD. We detected mild dystonic signs in eight cases. In particular, five of them presented cranial dyskinesias. No mutation of the GCH1 gene was found. The results of the urine biopterin and neopterin analysis and the oral Phe loading did not reveal biochemical abnormalities suggestive of reduced GCH1 activity. We confirm that some clinical features, namely the presence of focal or segmental dystonia, suggest an adult-onset dystonia in SWEDD cases. However, we exclude DRD caused by GCH1 gene mutations in the present series.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653–1661CrossRef Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653–1661CrossRef
2.
Zurück zum Zitat Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET Study Group (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93–101CrossRefPubMed Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET Study Group (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93–101CrossRefPubMed
3.
Zurück zum Zitat Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508CrossRefPubMed Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508CrossRefPubMed
4.
Zurück zum Zitat Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG (2006) Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 27:933–937CrossRefPubMed Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG (2006) Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 27:933–937CrossRefPubMed
5.
Zurück zum Zitat Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870CrossRefPubMed Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870CrossRefPubMed
6.
Zurück zum Zitat Silveira-Moriyama L, Schwingenschuh P, O’Donnell A, Schneider SA, Mir P, Carrillo F, Terranova C, Petrie A, Grosset DG, Quinn NP, Bhatia KP, Lees AJ (2009) Olfaction in patients with suspected Parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 80:744–748CrossRefPubMed Silveira-Moriyama L, Schwingenschuh P, O’Donnell A, Schneider SA, Mir P, Carrillo F, Terranova C, Petrie A, Grosset DG, Quinn NP, Bhatia KP, Lees AJ (2009) Olfaction in patients with suspected Parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 80:744–748CrossRefPubMed
7.
Zurück zum Zitat Schneider SA, Edwards MJ, Mir P, Cordivari C, Hooker J, Dickson J, Quinn N, Bhatia KP (2007) Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 22:2210–2215CrossRefPubMed Schneider SA, Edwards MJ, Mir P, Cordivari C, Hooker J, Dickson J, Quinn N, Bhatia KP (2007) Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 22:2210–2215CrossRefPubMed
8.
Zurück zum Zitat Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katshnig P, Carrillo F, Laura Silveira-Moriyama L, Schneider SA, Kägi G, Dickson J, Lees AJ, Quinn N, Mir P, Rothwell JC, Bhatia KP (2010) Adult onset asymmetric upper limb tremor misdiagnosed as Parkinson’s disease: a clinical and electrophysiological study. Mov Disord 25:560–569PubMedCentralCrossRefPubMed Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katshnig P, Carrillo F, Laura Silveira-Moriyama L, Schneider SA, Kägi G, Dickson J, Lees AJ, Quinn N, Mir P, Rothwell JC, Bhatia KP (2010) Adult onset asymmetric upper limb tremor misdiagnosed as Parkinson’s disease: a clinical and electrophysiological study. Mov Disord 25:560–569PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Segawa M (2003) Autosomal dominant GTP cyclohydrolase I (AD GCH 1) deficiency (Segawa disease, dystonia 5; DYT 5). Chang Gung Med J 32:1–11 Segawa M (2003) Autosomal dominant GTP cyclohydrolase I (AD GCH 1) deficiency (Segawa disease, dystonia 5; DYT 5). Chang Gung Med J 32:1–11
10.
Zurück zum Zitat Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, Fujita K, Nagatsu T (1994) Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8:236–242CrossRefPubMed Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, Nomura Y, Endo K, Tanaka H, Tsuji S, Fujita K, Nagatsu T (1994) Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 8:236–242CrossRefPubMed
11.
Zurück zum Zitat Nygaard TG, Trugman JM, de Yebenes JG, Fahn S (1990) Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology 40:66–69CrossRefPubMed Nygaard TG, Trugman JM, de Yebenes JG, Fahn S (1990) Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology 40:66–69CrossRefPubMed
12.
Zurück zum Zitat Trender-Gerhard I, Sweeney MG, Schwingenschuh P, Mir P, Edwards MJ, Gerhard A, Polke JM, Hanna MG, Davis MB, Wood NW, Bhatia KP (2009) Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 80:839–845CrossRefPubMed Trender-Gerhard I, Sweeney MG, Schwingenschuh P, Mir P, Edwards MJ, Gerhard A, Polke JM, Hanna MG, Davis MB, Wood NW, Bhatia KP (2009) Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 80:839–845CrossRefPubMed
13.
Zurück zum Zitat Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB (1998) Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 43:792–800CrossRefPubMed Jeon BS, Jeong JM, Park SS, Kim JM, Chang YS, Song HC, Kim KM, Yoon KY, Lee MC, Lee SB (1998) Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 43:792–800CrossRefPubMed
14.
Zurück zum Zitat Furukawa Y, Nishi K, Kondo T, Mizuno Y, Narabayashi H (1993) CSF biopterin levels and clinical features of patients with juvenile parkinsonism. Adv Neurol 60:562–567PubMed Furukawa Y, Nishi K, Kondo T, Mizuno Y, Narabayashi H (1993) CSF biopterin levels and clinical features of patients with juvenile parkinsonism. Adv Neurol 60:562–567PubMed
15.
Zurück zum Zitat Bandmann O, Goertz M, Zschocke J, Deuschl G, Jost W, Hefter H, Müller U, Zöfel P, Hoffmann G, Oertel W (2003) The phenylalanine loading test in the differential diagnosis of dystonia. Neurology 60:700–702CrossRefPubMed Bandmann O, Goertz M, Zschocke J, Deuschl G, Jost W, Hefter H, Müller U, Zöfel P, Hoffmann G, Oertel W (2003) The phenylalanine loading test in the differential diagnosis of dystonia. Neurology 60:700–702CrossRefPubMed
16.
Zurück zum Zitat Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Longo K, Cozzolino A, Giordano F, De Rosa A, De Michele G, Pellecchia MT, Barone P (2013) Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84:14–17CrossRefPubMed Erro R, Picillo M, Vitale C, Amboni M, Moccia M, Longo K, Cozzolino A, Giordano F, De Rosa A, De Michele G, Pellecchia MT, Barone P (2013) Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84:14–17CrossRefPubMed
17.
Zurück zum Zitat Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCentralCrossRefPubMed Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCentralCrossRefPubMed
18.
Zurück zum Zitat Segawa M, Nomura Y, Nishiyama N (2003) Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 54:S32–S45CrossRefPubMed Segawa M, Nomura Y, Nishiyama N (2003) Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 54:S32–S45CrossRefPubMed
19.
Zurück zum Zitat Antonozzi I, Carducci C, Vestri L, Pontecorvi A, Moretti F (1988) Rapid and sensitive method for high-performance liquid chromatographic analysis of pterins in biological fluids. J Chromatogr 459:319–324CrossRefPubMed Antonozzi I, Carducci C, Vestri L, Pontecorvi A, Moretti F (1988) Rapid and sensitive method for high-performance liquid chromatographic analysis of pterins in biological fluids. J Chromatogr 459:319–324CrossRefPubMed
20.
Zurück zum Zitat Hyland K, Fryburg JS, Wilson WG, Bebin EM, Arnold LA, Gunasekera RS, Jacobson RD, Rost-Ruffner E, Trugman JM (1997) Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. Neurology 48:1290–1297CrossRefPubMed Hyland K, Fryburg JS, Wilson WG, Bebin EM, Arnold LA, Gunasekera RS, Jacobson RD, Rost-Ruffner E, Trugman JM (1997) Oral phenylalanine loading in dopa-responsive dystonia: a possible diagnostic test. Neurology 48:1290–1297CrossRefPubMed
21.
Zurück zum Zitat Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF (1993) Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 39:66–71PubMed Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF (1993) Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 39:66–71PubMed
22.
Zurück zum Zitat Saunders-Pullmana R, Blau N, Hyland K, Zschocke J, Nygaard T, Raymond D, Shanker V, Mohrmann K, Arnold L, Tabbal S, deLeon D, Ford B, Brin M, Chouinard S, Ozelius L, Klein C, Bressman SB (2004) Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Mol Genet Metabol 83:207–212CrossRef Saunders-Pullmana R, Blau N, Hyland K, Zschocke J, Nygaard T, Raymond D, Shanker V, Mohrmann K, Arnold L, Tabbal S, deLeon D, Ford B, Brin M, Chouinard S, Ozelius L, Klein C, Bressman SB (2004) Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Mol Genet Metabol 83:207–212CrossRef
23.
Zurück zum Zitat Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510CrossRefPubMed Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510CrossRefPubMed
24.
Zurück zum Zitat Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K (2004) (23I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 61:1224–1229CrossRefPubMed Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K (2004) (23I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 61:1224–1229CrossRefPubMed
25.
Zurück zum Zitat Utiumi MA, Felício AC, Borges CR, Braatz VL, Rezende SA, Munhoz RP, Bressan RA, Ferraz HB, Teive HA (2012) Dopamine transporter imaging in clinically unclear cases of parkinsonism and the importance of scans without evidence of dopaminergic deficit (SWEDDs). Arq Neuropsiquiatr 70:667–673CrossRefPubMed Utiumi MA, Felício AC, Borges CR, Braatz VL, Rezende SA, Munhoz RP, Bressan RA, Ferraz HB, Teive HA (2012) Dopamine transporter imaging in clinically unclear cases of parkinsonism and the importance of scans without evidence of dopaminergic deficit (SWEDDs). Arq Neuropsiquiatr 70:667–673CrossRefPubMed
26.
Zurück zum Zitat Sixel-Doring F, Liepe K, Mollenhauer B, Trautmann E, Trenkwalder C (2011) The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 258:2147–2154CrossRefPubMed Sixel-Doring F, Liepe K, Mollenhauer B, Trautmann E, Trenkwalder C (2011) The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 258:2147–2154CrossRefPubMed
27.
Zurück zum Zitat Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D, Parkinson Study Group PRECEPT Investigators (2014) Longitudinal follow-up of SWEDD subjects in the PRECEPT study. Neurology 82:1791–1797PubMedCentralCrossRefPubMed Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, Hyson C, Jennings D, Parkinson Study Group PRECEPT Investigators (2014) Longitudinal follow-up of SWEDD subjects in the PRECEPT study. Neurology 82:1791–1797PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Leuzzi V, Carducci C, Chiarotti F, D’Agnano D, Giannini MT, Antonozzi I, Carducci C (2013) Urinary neopterin and phenylalanine loading test as tools for the biochemical diagnosis of Segawa disease. JIMD Rep 7:67–75PubMedCentralCrossRefPubMed Leuzzi V, Carducci C, Chiarotti F, D’Agnano D, Giannini MT, Antonozzi I, Carducci C (2013) Urinary neopterin and phenylalanine loading test as tools for the biochemical diagnosis of Segawa disease. JIMD Rep 7:67–75PubMedCentralCrossRefPubMed
Metadaten
Titel
Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD)
verfasst von
Anna De Rosa
Claudia Carducci
Carla Carducci
Silvio Peluso
Maria Lieto
Andrea Mazzella
Francesco Saccà
Vincenzo Brescia Morra
Sabina Pappatà
Vincenzo Leuzzi
Giuseppe De Michele
Publikationsdatum
01.11.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 11/2014
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7477-6

Weitere Artikel der Ausgabe 11/2014

Journal of Neurology 11/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.